Sun Pharma announced successful Phase III confirmatory clinical trial results for Seciera (cyclosporine A, 0.09% ophthalmic solution), for the treatment...
Assessment of the safety and the efficacy of a tacrolimus modified release (FK506MR) based immunosuppressive regimen in stable kidney transplant subjects converted from a cyclosporin based immunosuppressive regimen.
Viatris Inc. announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis. There are no remaining legal or regulatory barriers, and the company is launching immediately.